WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical firm pioneering the invention and growth of a brand new era of immuno-oncology therapeutics for sufferers, at present introduced a poster presentation of preclinical information on EOS-984, a possible first-in-class small molecule inhibitor concentrating on the equilibrative nucleoside transporter 1 (ENT1) in oncology, on the American Affiliation for Most cancers Analysis (AACR) Annual Assembly, being held April 5-10, 2024 in San Diego, California.
Primarily based on the Firm’s discovery and characterization of ENT1 in adenosine-mediated immunosuppression, this novel mechanism permits for the intracellular accumulation of adenosine, which then suppresses proliferation and effector operate of T cells within the excessive adenosine tumor microenvironment. In mouse fashions, deletion of ENT1 led to potent management of tumor proliferation and elevated CD8+ T cell frequency, proliferation, and cytokine manufacturing inside tumors, additional supporting ENT1’s function in tumor progress. In preclinical research, blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of reminiscence T cells and TILs regardless of excessive adenosine concentrations, ensuing within the restoration of T cell operate and enhanced tumor cell killing. Moreover, mixture of EOS-984 with anti-PD-1 remedy synergistically led to the management of tumor progress in a humanized mouse mannequin of triple detrimental breast most cancers proof against anti-PD-1 blockade. Because of its mechanism of motion, EOS-984 holds potential as a mixture accomplice past anti-PD-1 remedy, together with different immuno-oncology brokers, cell therapies, and bispecific T cell engagers.
EOS-984 is presently within the dose escalation portion of a Section 1 trial in superior malignancies. Topline information from the Section 1 trial is anticipated within the second half of 2024.
Abstracts can be found on AACR’s web site situated at www.aacr.org. Posters might be archived within the Traders part of the Firm’s web site situated at www.iteostherapeutics.com.
Poster Presentation Particulars
Title: “Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression”
Session Title: Experimental and Molecular Therapeutics: Tumor Microenvironment
Summary Quantity: 734
Date and Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Part 29
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical firm pioneering the invention and growth of a brand new era of immuno-oncology therapeutics for sufferers. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to revive the immune response in opposition to most cancers. The Firm’s progressive pipeline contains three clinical-stage applications concentrating on novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved medical outcomes, together with the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a analysis middle in Gosselies, Belgium.
About EOS-984
EOS-984 is a possible first-in-class small molecule concentrating on the equilibrative nucleoside transporter 1 (ENT1) designed to inhibit the immunosuppressive exercise of adenosine and restore immune cell proliferation. The therapeutic candidate has the potential to totally reverse the profound immunosuppressive motion of adenosine on T and B cells and is in Section 1 growth.
Web Posting of Data
iTeos Therapeutics routinely posts info that could be vital to buyers within the ‘Traders’ part of its web site at www.iteostherapeutics.com. The corporate encourages buyers and potential buyers to seek the advice of our web site repeatedly for vital details about iTeos Therapeutics.
Ahead-Wanting Statements
This press launch comprises forward-looking statements. Any statements that aren’t solely statements of historic reality are forward-looking statements. Phrases equivalent to “imagine,” “anticipate,” “plan,” “count on,” “will,” “might,” “intend,” “put together,” “look,” “potential,” “doable” and related expressions are meant to determine forward-looking statements. These forward-looking statements embody statements referring to the potential advantages of EOS-984, the potential of EOS-984 to be first-in-class, and EOS-984’s potential as a mixture accomplice past anti-PD-1 remedy, together with different immuno-oncology brokers, cell therapies, and bispecific T cell engagers.
These forward-looking statements contain dangers and uncertainties, lots of that are past iTeos’ management. Precise outcomes might materially differ from these acknowledged or implied by these forward-looking statements because of such dangers and uncertainties. Identified threat components embody the next: success in preclinical testing and early medical trials doesn’t be certain that later medical trials might be profitable; the info for our product candidates is probably not ample for acquiring regulatory approval to maneuver into later stage trials or to commercialize merchandise; iTeos might not be capable to execute on its enterprise plans, together with assembly its anticipated or deliberate regulatory milestones and timelines, analysis and medical growth plans, and bringing its product candidates to market, for numerous causes, a few of which can be exterior of iTeos’ management, together with doable limitations of firm monetary and different sources, manufacturing limitations that is probably not anticipated or resolved for in a well timed method, detrimental developments within the discipline of immuno-oncology, equivalent to opposed occasions or disappointing outcomes, together with in reference to competitor therapies, and regulatory, court docket or company selections equivalent to selections by the USA Patent and Trademark Workplace with respect to patents that cowl our product candidates; and people dangers recognized below the heading “Danger Elements” in iTeos’ Annual Report on Type 10-Okay for the yr ended December 31, 2023 filed with the Securities and Alternate Fee (SEC) in addition to different SEC filings made by the Firm which you’re inspired to evaluate.
Any of the foregoing dangers might materially and adversely have an effect on iTeos’ enterprise, outcomes of operations and the buying and selling worth of iTeos’ frequent inventory. We warning buyers to not place appreciable reliance on the forward-looking statements contained on this press launch. iTeos doesn’t undertake any obligation to publicly replace its forward-looking statements apart from as required by regulation.
For additional info, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
The submit iTeos Presents EOS-984 Preclinical Knowledge Demonstrating Restoration of T Cell Exercise from Adenosine Suppression on the American Affiliation for Most cancers Analysis Annual Assembly 2024 appeared first on FinanceGrabber.